Insulet Expands Omnipod 5 Automated Insulin Delivery System to Australia and Three Additional Markets
Key Insights
Insulet's tubeless Omnipod 5 (search) Automated Insulin Delivery System is now commercially available in Australia and will soon launch in Belgium, Canada, and Switzerland, expanding access to thousands more diabetes (search) patients globally.
The system integrates with continuous glucose monitors from Dexcom (search) (G6 and G7) and Abbott's FreeStyle Libre 2 Plus (search), automatically adjusting insulin delivery every five minutes using SmartAdjust technology.
Insulet plans further expansion to five additional Middle Eastern markets including Israel, Saudi Arabia, UAE, Qatar, and Kuwait, strengthening its global leadership position in automated insulin delivery technology.
Insulet Corporation (NASDAQ: PODD) has announced the expansion of its Omnipod 5 (search) Automated Insulin Delivery (AID) System to four new international markets, furthering the company's global reach in tubeless insulin pump technology.
The revolutionary diabetes (search) management system is now commercially available in Australia with Dexcom (search) G6 and G7 compatibility, with plans to add Abbott's FreeStyle Libre 2 Plus (search) integration soon. The company also revealed plans to launch in Belgium within weeks, followed by Canada and Switzerland later this spring.
"Bringing our life-changing flagship Omnipod 5 (search) to people living with diabetes (search) in these four new countries is both incredibly exciting and meaningful, further cementing our leadership position worldwide," said Pat Crannell, Senior Vice President and International General Manager at Insulet. "We're transforming diabetes management, delivering real-world benefits for our customers to help make diabetes a smaller part of their busy lives."
Advanced Technology Simplifies Diabetes Management
The Omnipod 5 (search) System represents a significant advancement in diabetes (search) care, eliminating the need for multiple daily injections while automatically adjusting insulin delivery every five minutes. The system's SmartAdjust™ technology communicates with compatible continuous glucose monitors (CGMs) to proactively correct high glucose levels and help protect against lows, both day and night.
As the first tubeless automated insulin delivery system on the market, Omnipod 5 (search) offers a waterproof, discreet, and wearable solution that simplifies diabetes (search) management. The system has demonstrated improved clinical outcomes in real-world settings.
Kimmie Patel, whose five-year-old daughter Priya currently uses Omnipod DASH (search) in Australia, expressed enthusiasm about upgrading to the new system: "We're really excited for Priya to start on Omnipod 5 (search). She's a bright, energetic little girl and managing her diabetes (search) has always been a part of her routine. School is such an important part of her life now, and knowing that she can just be a kid without constantly worrying about her insulin delivery is a huge relief."
Clinical Significance and Healthcare Provider Support
The expansion comes at a time when automated insulin delivery systems are increasingly recognized as the standard of care for type 1 diabetes (search) management. Dr. Ilana Halperin, an endocrinologist at Sunnybrook Health Sciences Centre in Toronto, Canada, highlighted the significance of the upcoming Canadian launch.
"Canadians living with type 1 diabetes (search) have been anxiously awaiting the arrival of Omnipod 5 (search), the only tubeless commercial AID System. In keeping with our new Diabetes (search) Canada Guidelines that all people with type 1 diabetes should use an AID System, the arrival of Omnipod 5 will be life changing for many people living with diabetes and their families," Dr. Halperin stated.
Expanding Global Footprint
The announcement precedes Insulet's participation in the 18th International Conference on Advanced Technologies & Treatments for Diabetes (search), where the company will present new clinical data on the direct transition from multiple daily injections to Omnipod 5 (search) in adults and children with type 1 diabetes (search).
This expansion follows successful launches in the United States, United Kingdom, Germany, France, the Netherlands, Italy, and Nordic countries. Insulet has also recently expanded sensor integrations to include Dexcom (search) G7 for Omnipod 5 (search) users in the UK and the Netherlands.
Looking ahead, Insulet plans to bring Omnipod 5 (search) to five additional markets: Israel, Saudi Arabia, the United Arab Emirates, Qatar, and Kuwait. The company indicated that timing details for these launches will be shared in the coming months.
System Compatibility and Integration
A key feature of the Omnipod 5 (search) expansion is its compatibility with multiple continuous glucose monitoring systems. The specific integrations vary by market:
- Australia: Currently compatible with Dexcom G6 and G7, with plans to add Abbott's FreeStyle Libre 2 Plus
- Belgium: Will launch with Abbott's FreeStyle Libre 2 Plus and Dexcom G6 and G7 integrations
- Canada: Will launch with Dexcom G6 and G7 compatibility
- Switzerland: Will offer Abbott's FreeStyle Libre 2 Plus and Dexcom G6 and G7 integrations
This multi-sensor approach provides flexibility for patients and healthcare providers to choose the CGM system that best meets individual needs while benefiting from the Omnipod 5 (search)'s automated insulin delivery capabilities.
Market Impact and Business Significance
The global expansion strengthens Insulet's position as a leader in tubeless insulin pump technology. By entering these new markets, the company extends its reach to thousands more people with diabetes (search) worldwide who can benefit from automated insulin delivery.
The Omnipod 5 (search) system, with its tubeless design and smartphone control capabilities, represents Insulet's flagship innovation in diabetes (search) management technology. The company continues to leverage its unique Pod design for potential applications beyond insulin delivery, exploring opportunities for non-insulin subcutaneous drug delivery across other therapeutic areas.